Nice to see you have closed out your short Ptolemic.So at this stage you are now neutral regarding the SP of MAD?And if MAD continues to show uptrend in production, and if they have further results from the high impact initiative, you'll go long?
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling